Fresenius Kabi AG
Division of Fresenius SE & Co. KGaA
www.fresenius-kabi.com
Latest From Fresenius Kabi AG
Strides Plans Re-Entry On Injectables
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.
Strides Plans Injectables Re-entry As Mylan Non-Compete Nears End
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
Kabi Commits To Biosimilars Development
Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.
Company Information
- Industry
-
Medical Devices
- Infusion Therapy Equipment and Supplies
-
Pharmaceuticals
- Generic Drugs
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Fresenius SE & Co. KGaA
- Senior Management
- Rainer Baule, Chmn. & CEO
- Contact Info
-
Fresenius Kabi AG
Phone: (49) 6172 686 0
Else-Kröner-Straße 1
Bad Homburg , 61352
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice